DE-THE-LYCRA-COMPANY
27.8.2024 11:01:33 CEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative fiber and technology solutions for the apparel and personal care industries, announced today that it is showcasing its sustainable offerings and more at Intertextile Shanghai from August 27 to 29. The LYCRA Company Pavilion in Hall 4.1 (Booth E56) features 931 square meters of exhibit space and 25 co-exhibitors united under the theme “Accelerating Our Journey to Decarbonization.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240827097449/en/
The LYCRA Company is showcasing its sustainable offerings and more at Intertextile Shanghai from August 27 to 29. Its pavilion in Hall 4.1 (Booth E56) features 25 co-exhibitors united under the theme “Accelerating Our Journey to Decarbonization.” Visitors to the Econogy Hub (Hall 5.1, Booth A36) will discover through an immersive experience in a replica cornfield how bio-derived LYCRA® fiber made with QIRA® can help accelerate decarbonization in the fashion industry. (Photo: Business Wire)
The LYCRA Company will highlight products designed to meet consumer needs and help reduce the environmental impact of apparel products:
- Bio-derived LYCRA® fiber made with QIRA®, the industry’s first renewable spandex available at scale, will launch in the first half of 2025. Made from annually grown field corn, it's expected to reduce the carbon footprint of LYCRA® fiber by up to 44 percent* while delivering equivalent performance to the original fiber. Visitors to the Econogy Hub (Hall 5.1, Booth A36) will discover through an immersive experience in a replica cornfield how this patented innovation can help accelerate decarbonization in the fashion industry.
- LYCRA® FiT400™ fiber is a unique bicomponent fiber engineered to optimize the comfort and performance of knits while delivering a durable, soft hand feel, all-day stretch, long-lasting fit, and cooling comfort. This Global Recycled Standard-certified fiber contains 60% recycled PET and 14.4% bio-derived resources.
- COOLMAX® EcoMade fiber made from 100% textile waste delivers cool and dry comfort to various garment types, while THERMOLITE® EcoMade fiber made from 100% textile waste adds lightweight warmth.
“We are thrilled to showcase our sustainable solutions at Intertextile that will help our customers reduce their carbon footprint and support their sustainability goals,” said Jason Wang, vice president, Asia. “We look forward to helping attendees find the consumer-driven, market-relevant branded solutions they need to take their business to the next level.”
The LYCRA Company will also showcase LYCRA® ADAPTIV fiber, one of the company’s fastest-growing products. Brands and retailers worldwide appreciate how it enables inclusive sizing and delivers a second-skin fit, enhanced comfort in motion, and greater functionality to activewear, intimate apparel, denim, and more. Regina Miracle, a leading garment maker and a key value chain partner of The LYCRA Company, will exhibit garment samples.
The booth will also feature garment samples of new LYCRA FitSense® denim technology, a targeted shaping innovation for stretch denim to deliver a customizable fit to different body types and shapes, a breakthrough for the industry launched this year. Through a combination of fiber, fabric, and garment processing technologies, this discreet and invisible solution retains the authentic denim look and feel that consumers desire.
To learn more about The LYCRA Company’s latest innovations and commitment to a more sustainable future, visit Intertextile Booth E56 in Hall 4.1 and Booth A36 in Hall 5.1, or visit this website.
*Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at lycra.com.
LYCRA®, LYCRA® FiT400™, LYCRA FitSense®, COOLMAX® and THERMOLITE® are trademarks of The LYCRA Company.
QIRA® is a trademark of Qore®.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827097449/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom